SecBot SecBot
PRESS-RELEASE ·Filed Mar 10, 2026

ARTV

Artiva Biotherapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should monitor upcoming clinical data in H1 2026 for AlloNK in refractory RA, which could serve as a key catalyst. Despite growing losses and zero revenue, the cash runway provides near-term stability, reducing immediate dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.13
T+0 close · Mar 10, 2026 · via day close
Latest settled
−2.24%
T+60 · $6.97
Vs SPY
−13.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 11 $7.13entry
  2. T+1 · 8mo ago −5.33%α −3.85% · $6.75
  3. T+5 · 8mo ago −18.65%α −16.47% · $5.80
  4. T+20 · 7mo ago −4.63%α −5.15% · $6.80
  5. T+60 · 6mo ago −2.24%α −13.77% · $6.97
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Artiva Biotherapeutics reported its full-year 2025 financial results, highlighting a net loss of $83.9 million, increased R&D spending, and a strong cash position of $108.0 million that funds operations into Q2 2027. The company emphasized clinical progress with AlloNK in refractory rheumatoid arthritis, including FDA Fast Track designation and upcoming data readouts in H1 2026, but reported zero revenue for the year.

Key Financial Metrics

Revenue
$0.00
-100.0% YoY
EPS
$-3.43

Key Facts

  • Net loss was $83.9 million in 2025 vs. $65.4 million in 2024
  • Cash, cash equivalents, and investments totaled $108.0 million as of December 31, 2025, down from $185.4 million in 2024
  • Cash runway extends into Q2 2027
  • License and development support revenue was $0 in 2025 vs. $0.3 million in 2024
  • R&D expenses increased to $69.5 million from $50.3 million in 2024
  • Initial clinical response data in refractory RA expected in first half of 2026
  • FDA interaction planned in first half of 2026 to discuss pivotal trial design

Financial Impact

Increased R&D spend by $19.2 million YoY; cash burn of ~$77.4 million (net loss plus non-cash items); revenue declined to zero

revenuenet losscashR&D expenses

Risk Factors

  • High cash burn with no current revenue stream
  • Clinical data in H1 2026 may not meet expectations, risking valuation decline

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3253311

Track record

33 reports on ARTV

Performance horizon

11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 8h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 10, 2026